ClinicalTrials.gg
Active, not recruitingNCT06551324MEVPRO-1Updated Oct 30, 2026

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

A Phase 3 interventional study of PF-06821497 and Docetaxel in Metastatic Castrate Resistant Prostate Cancer (mCRPC), sponsored by Pfizer. Active, not recruiting at 224 sites in 23 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Updated Oct 30, 2026Primary completion movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
609
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Prostatic Neoplasms by Pfizer — 3 open to participants now, 8 under way, 5 of them phase 3. Prostatic Neoplasms · Pfizer.

Enrollment
8th of 33
609 · median 160
Started
2024
with 2 others
Phase 3
10 of 42
2 open now
Registered
37th of 42
by date

Among the 42 studies in Prostatic Neoplasms by Pfizer, this one is the 8th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 in phase 3, and was the 37th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 42 studies in Prostatic Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Prostatic Neoplasms by Pfizer, or all of them as a file.
02

Study summary

Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.

The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.

03

Conditions studied

  • Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Keywords

  • Prostate cancer
  • Enhancer of zeste homolog 2
  • castrate resistant prostate cancer
  • Hormone resistant
  • Metastatic hormone resistant prostate cancer
  • Metastatic castrate resistant prostate cancer
  • PF-06821497
  • Enzalutamide
  • Docetaxel
  • Advanced prostate cancer
  • Efficacy
  • Safety
  • Open-label
  • Relapsed
  • refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate without small cell features.
  • disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
  • Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or mCRPC setting is required.
  • Eastern Cooperate Oncology Group () performance status 0 - 2, with of at least 6 months as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may make the participant inappropriate for the study.
  • Know history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery.
  • cardiovascular disease.
  • Known or suspected or active or clinically significant history of seizure.
  • Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (i.e. 177Lu-PSMA-617, radium 223), androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy, CDK4/6 inhibitors, or other systemic anti-cancer treatment, with the following exceptions:

    1. Treatment with first-generation antiandrogen agents, if discontinued prior to first dose of study intervention.
    2. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion.
    3. Use of 5-alpha reductase inhibitors within 28 days of randomization.
  • Previous administration with an product within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is longer).
  • Inadequate organ function.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
609 participants (actual)

Study arms

  • Active comparator
    Arm B

    Comparator Arm B: Physician's choice of enzalutamide 160 mg QD or docetaxel 75 mg/m2 intravenous (IV) every 21 days

    Drug: Docetaxel · Drug: Enzalutamide

  • Experimental
    Arm A

    Investigational Arm A: PF-06821497 875 mg twice daily (BID) + enzalutamide 160 mg every day (QD)

    Drug: PF-06821497 · Drug: Enzalutamide

Interventions

  • 875 mg BID (2 times a day)

    Also known as: Mevrometostat

  • 75 mg/m2 IV (every 21 days)

    Also known as: Taxotere

  • 160 mg QD

    Also known as: XTANDI

06

What researchers measure

Primary outcomes

  1. Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)

    rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or in bone per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines by BICR, or death, whichever occurs first.

    Time frame: Randomization up to approximately 2 years.

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Randomization up to approximately 4.5 years.

  2. Objective Response (ORR)

    The objective response rate is defined as the proportion of participants with measurable soft tissue disease at baseline who have a confirmed objective response of complete response (CR) or partial response (PR) per RECIST v1.1.

    Time frame: Randomization up to approximately 2 years.

  3. Duration of Response (DoR) in measurable soft tissue disease

    The DoR is defined as the first objective evidence of soft tissue response (CR or PR, whichever is earlier) to radiographic progression or death due to any cause whichever occurs first.

    Time frame: Randomization up to approximately 2 years.

  4. Time to prostate specific antigen (PSA) progression.

    Proportion of participants with PSA response ≥50% in participants with detectable PSA values at baseline.

    Time frame: Randomization up to approximately 2 years.

  5. Time to initiation of antineoplastic therapy.

    Time from randomization to first use of new antineoplastic therapy.

    Time frame: Randomization up to approximately 4.5 years.

  6. Prostate Specific Antigen Response

    Proportion of participants with PSA response ≥50% in participants with detectable PSA values at baseline.

    Time frame: Randomization up to approximately 2 years.

  7. Incidence of Adverse Events

    Type, incidence, severity \[as graded by National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v5.0\], seriousness and relationship to study medications of AEs.

    Time frame: Randomization up to approximately 4.5 years

  8. Time to first symptomatic skeletal event

    Time from randomization to first symptomatic skeletal event (symptomatic bone fractures, spinal cord compression, surgery or radiation to the bone whichever is first).

    Time frame: Randomization up to approximately 2 years.

  9. Change from baseline in patient reported pain symptoms per Brief Pain Inventory-Short Form (BPI-SF)

    Analysis of Brief Pain Inventory-Short Form (BPI-SF) will be based on the pain severity score (mean of individual BPI-SF items 3, 4, 5 and 6), the pain interference score (mean of items 9A-9G), and the single BPI-SF Item 3 which asks the patient to rate pain at its worst in the last 24 hours.

    Time frame: Randomization up to approximately 4.5 years

  10. Change from baseline in health-related quality of life (HRQoL) per Functional Assessment of Cancer Therapy - Prostate (FACT-P)

    Change from baseline in HRQoL (FACT-P total score) will be presented. The FACT-P total score will be calculated based on the participant responses to the 39 items in the FACT-P questionnaire. Each item is rated on a 0 to 4 Likert-type scale and then combined to produce the FACT-P total score (0-156), with higher scores representing better health-related quality of life.

    Time frame: Randomization to approximately 4.5 years

  11. Change from baseline in social/family well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)

    Change from baseline in social/family well-being score will be presented. The social/family well-being score will be calculated based on 7 items in the FACT-P questionnaire; score range 0-28. Each item is rated on a 0 to 4 Likert-type scale

    Time frame: Randomization up to approximately 4.5 years

  12. Change from baseline in emotional well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)

    Change from baseline in emotional well-being score will be presented. The emotional well-being score will be calculated based on 6 items in the FACT-P questionnaire; score range 0-24. Each item is rated on a 0 to 4 Likert-type scale

    Time frame: Randomization up to approximately 4.5 years

  13. Change from baseline in functioning well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)

    Change from baseline in functioning well-being score will be presented. The functioning well-being score will be calculated based on 7 items in the FACT-P questionnaire; score range 0-28. Each item is rated on a 0 to 4 Likert-type scale

    Time frame: Randomization up to approximately 4.5 years

  14. Change from baseline in physical well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)

    Change from baseline in physical well-being score will be presented. The physical well-being score will be calculated based on 7 items in the FACT-P questionnaire; score range 0-28. Each item is rated on a 0 to 4 Likert-type scale

    Time frame: Randomization to approximately 4.5 years

  15. Change from baseline in symptoms per Functional Assessment of Cancer Therapy - Prostate (FACT-P)

    Change from baseline prostate cancer symptoms (PCS) score will be presented. The PCS score will be calculated based on 12 items in the FACT-P questionnaire; score range 0-48. Each item is rated on a 0 to 4 Likert-type scale

    Time frame: Randomization up to approximately 4.5 years

  16. Change from baseline in patient reported health status per European Quality of Life 5-Dimension 5 Level (EQ-5D-5L)

    Participants will self-rate their current state of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression by choosing 1 of 5 possible responses that record the level of severity (no problems, slight problems, moderate problems, severe problems, or extreme problems) within each dimension. The questionnaire also includes a visual analog scale to self-rate general health state on a scale from "the worst health you can imagine" to "the best health you can imagine."

    Time frame: Randomizaton up to approximately 4.5 years

  17. Symptomatic toxicity as measured by items from the Patient-Reported Outcome CTCAE (PRO-CTCAE)

    Each selected PRO-CTCAE items will be assessed related to one or more attributes that include counts for the frequency, severity, and/or interference with usual or daily activities.

    Time frame: Randomization up to approximately 4.5 years

  18. Overall side effect burden as measured by the FACT- GP5

    The FACT-GP5 question assesses overall side effect burden with the following response options "I am bothered by side effects of treatment," is rated on a 5-point scale ranging from "not at all" (0) to "very much" (4) and counts will be presented.

    Time frame: Randomization to approximately 4.5 years

  19. Time to confirmatory deterioration in patient-reported pain symptoms per BPI-SF Item 3 "worst pain in 24 hours"

    Defined as the time from randomization to onset of pain progression, which is defined as \> 2-point increase from baseline in the score from the BPI-SF Question 3 that is confirmed at the next consecutive assessment \> 4 weeks apart or an initial deterioration followed by death before the next assessment

    Time frame: Randomization up to approximately 4.5 years

  20. Time to definitive deterioration in patient-reported health related quality of life (HRQoL) per FACT-P

    Defined as the time from randomization to onset of definitive deterioration in FACT-P total score, which is defined as \>10 point decrease from baseline and no subsequent observations with a \<10 point decrease from baseline FACT-P total score

    Time frame: Randomization up to approximately 4.5 years

  21. Time to definitive deterioration in patient-reported physical well-being per FACT-P

    Time to definitive deterioration in physical well-being (PWB) per FACT-P is defined as the time from randomization to onset of definitive deterioration in physical well-being, which is defined as ≥3-point

    Time frame: Randomization up to approximately 4.5 years

  22. To evaluate the PK of PF-06821497 when dosed with enzalutamide

    PK characterized by pre-dose trough and post-dose plasma concentrations of PF-06821497 at selected visits.

    Time frame: Cycle 1 (each cycle is 28 days), Day 1 to last PK draw at the end of Cycle 6, Day 1.

  23. To assess circulating tumor DNA (ctDNA) at baseline and on treatment to evaluate tumor burden.

    Evaluation of ctDNA burden at baseline and on study.

    Time frame: Baseline up to approximately 2 years.

07

Study locations

224 sites

Showing the first 100 of 224 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Shore ND, Fizazi K, Schweizer MT, Castro E, Azad AA, George DJ, da Trindade KM, Zeng H, Shrivastava N, Tonkovyd S, Bock A, Nekkalapudi S, Tang Y, Lin S, Agarwal N. Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols. Future Oncol. 2026 May;22(12):1397-1408. doi: 10.1080/14796694.2026.2667441. Epub 2026 May 10. PubMed 42108644 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Feb 2027, 28 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 28 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Feb 2027, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Aug 13, 2024
StartActual
Oct 21, 2024
Primary completionEst.
Feb 28, 2027was Dec 2026
CompletionEst.
Oct 29, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 28, 2026→Feb 28, 2027
Oct 30, 2026
Enrollment
600 (estimated)→609 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Dec 28, 2026→Feb 28, 2027
    Enrollment 600 (estimated)→609 (actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06551324
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 13, 2024
Start date
Oct 21, 2024
Primary completion
Feb 28, 2027 (estimated)
Completion
Oct 29, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mevrometostat

Start the discussion